Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

交易中 07-10 11:15:53 EDT

42.09

-0.74

-1.74%

最高42.92	最低41.67	成交量31.11万
今开42.92	昨收42.83	日振幅2.92%
总市值66.98亿	流通市值66.39亿	总股本1.59亿
成交额1,311万	换手率0.20%	流通股本1.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":42.085,"timestamp":1752160538591,"preClose":42.83,"halted":0,"volume":311085,"delay":0,"floatShares":157749379,"shares":159159099,"eps":-2.997331,"marketStatus":"交易中","change":-0.745,"latestTime":"07-10 11:15:53 EDT","open":42.92,"high":42.92,"low":41.67,"amount":13112316.74295,"amplitude":0.029185,"askPrice":42.15,"askSize":260,"bidPrice":42.02,"bidSize":96,"shortable":3,"etf":0,"ttmEps":-2.997331,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1752177600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":42.83,"preHourTrading":{"tag":"盘前","latestPrice":43.0299,"preClose":42.83,"latestTime":"09:13 EDT","volume":351,"amount":15112.15056,"timestamp":1752153236503},"postHourTrading":{"tag":"盘后","latestPrice":42.83,"preClose":42.83,"latestTime":"18:21 EDT","volume":83468,"amount":3574484.46,"timestamp":1752099696050},"volumeRatio":0.508794,"impliedVol":0.535,"impliedVolPercentile":0.892},"requestUrl":"/m/hq/s/IONS/tweets","defaultTab":"tweets","newsList":[{"id":"2548818467","title":"Ionis Pharmaceuticals, Inc.盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2548818467","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548818467?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:02","pubTimestamp":1751464955,"startTime":"0","endTime":"0","summary":"北京时间2025年07月02日22时02分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.07%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.70%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070222023597975e76&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2548006742","title":"Ionis Pharmaceuticals Raised to Overweight From Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2548006742","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548006742?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:06","pubTimestamp":1751371560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 01, 2025 08:06 ET (12:06 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"巴克莱银行将Ionis Pharmaceuticals从等权重上调至跑赢大盘","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2548907470","title":"Ionis Pharmaceuticals Inc : Barclays Raises Target Price to $57 From $51","url":"https://stock-news.laohu8.com/highlight/detail?id=2548907470","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548907470?lang=zh_cn&edition=full","pubTime":"2025-07-01 17:22","pubTimestamp":1751361727,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals Inc：巴克莱将目标价从51美元上调至57美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250701:nAZN42FCJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2548040435","title":"Ionis Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2548040435","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548040435?lang=zh_cn&edition=full","pubTime":"2025-07-01 10:00","pubTimestamp":1751335219,"startTime":"0","endTime":"0","summary":"Barclays upgraded Ionis Pharmaceuticals (IONS) to Overweight from Equal Weight with a price target of $57, up from $51, ahead of Tryngolza Phase 3 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-upgraded-to-overweight-from-equal-weight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"巴克莱银行将Ionis Pharmaceuticals评级从同等权重上调至跑赢大盘","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-upgraded-to-overweight-from-equal-weight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS"],"gpt_icon":0},{"id":"2546804787","title":"Ionis Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2546804787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546804787?lang=zh_cn&edition=full","pubTime":"2025-06-26 19:35","pubTimestamp":1750937700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 26, 2025 07:35 ET (11:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"HC Wainwright&Co.将Ionis Pharmaceuticals目标价维持在每股50.00澳元。","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2546224847","title":"TD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2546224847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546224847?lang=zh_cn&edition=full","pubTime":"2025-06-26 06:55","pubTimestamp":1750892108,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $59.00. The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-ionis-pharmaceuticals-ions-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"TD Cowen重申对Ionis Pharmaceuticals(IONS)的买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-reaffirms-their-buy-rating-on-ionis-pharmaceuticals-ions-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","IONS","TD"],"gpt_icon":0},{"id":"2546212044","title":"Biogen to Advance SMA Treatment Into Registrational Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2546212044","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546212044?lang=zh_cn&edition=full","pubTime":"2025-06-25 19:57","pubTimestamp":1750852620,"startTime":"0","endTime":"0","summary":"Biogen plans to advance an experimental treatment for the neuromuscular disease spinal muscular atrophy, or SMA, into registrational studies following encouraging results from an early-stage trial.Biogen on Wednesday said interim data from a Phase 1 study of salanersen show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of the drug.The Cambridge, Mass., biotechnology company said that based on the encouraging data, it is engaging with regulators to advance salanersen to registrational-stage studies.Biogen said salanersen uses the same mechanism of action as its Spinraza drug for SMA but is designed to achieve greater potency, giving it the potential to achieve high efficacy and enable once-yearly dosing.Biogen licensed the global development, manufacturing and commercialization rights for salanersen from Ionis Pharmaceuticals, which discovered the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Biogen将SMA治疗推进注册研究","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0234570918.USD","IE00B19Z9Z06.USD","BK4139","IE00B19Z9P08.USD","LU0109394709.USD","BIIB","BK4533","IONS","LU0889565916.HKD","BK4585","BK4588","LU0320765992.SGD","SMA","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2546230493","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546230493","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546230493?lang=zh_cn&edition=full","pubTime":"2025-06-25 03:02","pubTimestamp":1750791744,"startTime":"0","endTime":"0","summary":"北京时间2025年06月25日03时02分，Ionis Pharmaceuticals, Inc.股票出现异动，股价快速上涨5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.04%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250625030224978d39ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2544294831","title":"Bernstein Remains a Hold on Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2544294831","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544294831?lang=zh_cn&edition=full","pubTime":"2025-06-20 18:45","pubTimestamp":1750416352,"startTime":"0","endTime":"0","summary":"Bernstein analyst William Pickering maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report) yesterday. The company’s shares clos...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-ionis-pharmaceuticals-ions-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"伯恩斯坦仍持有Ionis Pharmaceuticals(IONS)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bernstein-remains-a-hold-on-ionis-pharmaceuticals-ions-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2542463517","title":"Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2542463517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542463517?lang=zh_cn&edition=full","pubTime":"2025-06-12 21:52","pubTimestamp":1749736320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 12, 2025 09:52 ET (13:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"摩根大通维持Ionis Pharmaceuticals中性评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2542151447","title":"Ionis Pharmaceuticals Announces Retirement of Chief Development Officer Dr. Richard Geary; Dr. Holly Kordasiewicz to Succeed in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151447","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151447?lang=zh_cn&edition=full","pubTime":"2025-06-12 21:00","pubTimestamp":1749733255,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Announces Retirement of Chief Development Officer Dr. Richard Geary; Dr. Holly Kordasiewicz to Succeed in January 2026. Ionis Pharmaceuticals Inc. has announced that Dr. Richard Geary, executive vice president and chief development officer, will retire effective January 2026. Dr. Holly Kordasiewicz, currently the senior vice president of neurology, will succeed him in the role. Dr. Geary, who joined Ionis in 1995, will continue to serve as a strategic consultant throughout 2026 to ensure a seamless transition. Dr. Kordasiewicz, with 20 years of experience in research and development, has been with Ionis since 2011 and will lead the company's neurology program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals宣布首席开发官Richard Geary博士退休；Holly Kordasiewicz博士将于2026年1月继任","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6rBrmX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2542128514","title":"Ionis Announces DR. Richard Geary, Chief Development Officer, to Retire; DR. Holly Kordasiewicz to Assume Role in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2542128514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542128514?lang=zh_cn&edition=full","pubTime":"2025-06-12 21:00","pubTimestamp":1749733203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis宣布首席开发官Richard Geary博士退休；Holly Kordasiewicz博士将于2026年1月上任","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nTUABJGYDQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2542358622","title":"Ionis Pharmaceuticals doses first patient in REVEAL study","url":"https://stock-news.laohu8.com/highlight/detail?id=2542358622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542358622?lang=zh_cn&edition=full","pubTime":"2025-06-11 19:10","pubTimestamp":1749640232,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals (IONS) announced that the first participant has been dosed in the global Phase 3 REVEAL study, which is designed to evaluate ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-doses-first-patient-in-reveal-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals为REVEAL研究中的第一名患者进行给药","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ionis-pharmaceuticals-doses-first-patient-in-reveal-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2542021585","title":"Ionis Pharmaceuticals Inc - First Patient Dosed in Phase 3 Reveal Study of Ion582 for Angelman Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2542021585","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542021585?lang=zh_cn&edition=full","pubTime":"2025-06-11 19:00","pubTimestamp":1749639655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals Inc-首位接受Ion582治疗Angelman综合征3期研究的患者","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nFWN3SD08B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2542850205","title":"Ionis Pharmaceuticals Initiates Phase 3 REVEAL Study of ION582 for Angelman Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2542850205","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542850205?lang=zh_cn&edition=full","pubTime":"2025-06-11 19:00","pubTimestamp":1749639618,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc. has announced the initiation of the pivotal Phase 3 REVEAL clinical study for ION582, targeting Angelman syndrome, a rare neurodevelopmental disorder. The first patient has been dosed, marking a significant step in evaluating the efficacy and safety of ION582. The study will involve approximately 200 participants worldwide, including both children and adults with a maternal UBE3A gene deletion or mutation. Participants will be randomized to receive either ION582 or a placebo over a 52-week period, with an extension phase offering the active treatment for up to two years. The primary endpoint focuses on improvements in expressive communication, with secondary endpoints assessing overall disease severity and other functional domains. Enrollment completion is anticipated in 2026. Results from the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals启动ION582治疗Angelman综合征的3期REVEAL研究","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL8Nq77l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2542318265","title":"Ionis Pharmaceuticals Inc. Conducted Virtual Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542318265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542318265?lang=zh_cn&edition=full","pubTime":"2025-06-10 18:02","pubTimestamp":1749549773,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc. held its virtual Annual Meeting of Stockholders on June 5, 2025. Stockholders considered several proposals during the meeting. The election of directors was approved by the stockholders. An amendment to the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan, which increases the aggregate number of shares authorized for issuance by 4,000,000 shares, was also approved. Additionally, the selection of Ernst & Young LLP as independent auditors for the 2025 fiscal year was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Ionis Pharmaceuticals Inc.召开虚拟年度股东大会","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDLbsLsQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2537873499","title":"Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2537873499","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537873499?lang=zh_cn&edition=full","pubTime":"2025-05-21 19:18","pubTimestamp":1747826282,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Mani Foroohar has maintained their bullish stance on IONS stock, giving a Buy rating yesterday. Mani Foroohar has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ionis-pharmaceuticals-buy-rating-affirmed-amid-promising-clinical-trial-results-and-future-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"Ionis Pharmaceuticals：在有希望的临床试验结果和未来前景中确认买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/ionis-pharmaceuticals-buy-rating-affirmed-amid-promising-clinical-trial-results-and-future-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS"],"gpt_icon":0},{"id":"2536821611","title":"Ionis Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2536821611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536821611?lang=zh_cn&edition=full","pubTime":"2025-05-20 19:09","pubTimestamp":1747739340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 20, 2025 07:09 ET (11:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"HC Wainwright&Co.将Ionis Pharmaceuticals目标价维持在每股50.00澳元。","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2536692506","title":"Ionis Pharmaceuticals’ Promising Future: Buy Rating Backed by Positive Phase 3 Study Results and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2536692506","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536692506?lang=zh_cn&edition=full","pubTime":"2025-05-20 17:06","pubTimestamp":1747732008,"startTime":"0","endTime":"0","summary":"Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/ionis-pharmaceuticals-promising-future-buy-rating-backed-by-positive-phase-3-study-results-and-upcoming-milestones?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"Ionis Pharmaceuticals充满希望的未来：积极的3期研究结果和即将到来的里程碑支持的买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/ionis-pharmaceuticals-promising-future-buy-rating-backed-by-positive-phase-3-study-results-and-upcoming-milestones?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IONS"],"gpt_icon":0},{"id":"2536633221","title":"William Blair Remains a Buy on Ionis Pharmaceuticals (IONS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2536633221","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536633221?lang=zh_cn&edition=full","pubTime":"2025-05-19 22:55","pubTimestamp":1747666518,"startTime":"0","endTime":"0","summary":"In a report released today, Myles Minter from William Blair reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-buy-on-ionis-pharmaceuticals-ions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"威廉·布莱尔仍买入Ionis Pharmaceuticals(IONS)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/william-blair-remains-a-buy-on-ionis-pharmaceuticals-ions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IONS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionispharma.com","stockEarnings":[{"period":"1week","weight":-0.0174},{"period":"1month","weight":0.1651},{"period":"3month","weight":0.6035},{"period":"6month","weight":0.28},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":0.2251}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1896},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.0648}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司在反义药物发明和开发上处于行业领先地位，利用新药研发平台，公司研发了大量的一流药品。反义技术在基因学和药物之间打开了一条通道。凭着公司高效多产的药物研发平台，公司可以用反义药物拓展自身及其合作伙伴的药物种类，满足大量的药物需求。公司的策略是做公司最擅长的事--寻找独特的反义药物并开发这些药物，使其成为关键的临床值转折点。公司发明并进行新药早期研究，然后将药物授权给合作伙伴。公司通过把药物交给领先的制药公司进行后期开发来实现药物的最大价值，如Biogen Idec公司、百时美施贵宝公司、 健赞公司、赛诺菲公司、葛兰素史克公司和礼来制药公司。 该公司的旗舰产品 KYNAMRO，正朝着市场上家族性高胆固醇血症患者迈进。 该公司于1989年在美国加州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.026725},{"month":2,"riseRate":0.5,"avgChangeRate":-0.015083},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.040983},{"month":8,"riseRate":0.555556,"avgChangeRate":0.014474},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.002333},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.044503},{"month":11,"riseRate":0.555556,"avgChangeRate":0.09545},{"month":12,"riseRate":0.444444,"avgChangeRate":0.0073}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}